Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Corroborated by 1 source from 1 publisher
globalcrime5h ago
TL;DR
According to seekingalpha.com, company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Huma Qamar - Chief Medical Officer Lejla Vajzovic Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Conference Call Participants Jay Chhablani Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Michael Okunewitch - Maxim Group LLC, Research Division Victor H.